Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F DiPersio

Showing results (71-80 of 342) with videos related to

Pageof 35
Sort By:
Transplantation and Cellular Therapy|July 25, 2022
Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving PerspectiveScott R Goldsmith, Armin Ghobadi, John F Dipersio, et al.
Blood|June 30, 2016
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trialsArmin Rashidi, Roland B Walter, Martin S Tallman, et al.
Bone Marrow Transplantation|January 26, 2018
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistanceMarcel van den Brink, Markus Uhrberg, Lorenz Jahn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2003
Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host diseaseMichael P Rettig, Julie K Ritchey, Todd E Meyerrose, et al.
Bone Marrow Transplantation|April 19, 2022
Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access programMark A Schroeder, Parameswaran N Hari, Amy Blithe, et al.
Blood Advances|December 11, 2019
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinibScott R Goldsmith, Sana Saif Ur Rehman, Cara L Shirai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2019
The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation CyclophosphamideJoseph Rimando, Michael Slade, John F DiPersio, et al.
Blood Advances|December 20, 2018
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftmentJoseph Rimando, Michael Slade, John F DiPersio, et al.
Cancer|March 7, 2017
Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantationChien-Jung Lin, Justin M Vader, Michael Slade, et al.
Plos One|October 8, 2014
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effectJaebok Choi, Matthew L Cooper, Bader Alahmari, et al.
Pageof 35

Showing results (71-80 of 342) with videos related to

Sort By:
Pageof 35
Transplantation and Cellular Therapy|July 25, 2022
Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving PerspectiveScott R Goldsmith, Armin Ghobadi, John F Dipersio, et al.
Blood|June 30, 2016
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trialsArmin Rashidi, Roland B Walter, Martin S Tallman, et al.
Bone Marrow Transplantation|January 26, 2018
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistanceMarcel van den Brink, Markus Uhrberg, Lorenz Jahn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 5, 2003
Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host diseaseMichael P Rettig, Julie K Ritchey, Todd E Meyerrose, et al.
Bone Marrow Transplantation|April 19, 2022
Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access programMark A Schroeder, Parameswaran N Hari, Amy Blithe, et al.
Blood Advances|December 11, 2019
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinibScott R Goldsmith, Sana Saif Ur Rehman, Cara L Shirai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 30, 2019
The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation CyclophosphamideJoseph Rimando, Michael Slade, John F DiPersio, et al.
Blood Advances|December 20, 2018
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftmentJoseph Rimando, Michael Slade, John F DiPersio, et al.
Cancer|March 7, 2017
Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantationChien-Jung Lin, Justin M Vader, Michael Slade, et al.
Plos One|October 8, 2014
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effectJaebok Choi, Matthew L Cooper, Bader Alahmari, et al.
Pageof 35